Form 4: Mineralys Therapeutics CFO Adam Levy Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Adam Levy, CFO and Secretary of Mineralys Therapeutics, sold 10,757 shares of common stock at a weighted-average price of $12.0558 per share on April 11, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 11, 2025, Adam Levy, the CFO and Secretary of Mineralys Therapeutics, sold 10,757 shares of the company's common stock.
- The sale was executed at a weighted-average price of $12.0558 per share.
- The transactions occurred within a price range of $11.78 to $12.35.
- The sale was conducted under a Rule 10b5-1 trading plan adopted on November 14, 2023.
- Following the transaction, Levy directly owns 215,340 shares of Mineralys Therapeutics.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.
Industry Context
Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of insider trading. The market typically views these sales in the context of the overall trading volume and the individual's holdings.
Comparison to Industry Standards
- Executive stock sales are a regular part of corporate compensation and financial planning.
- Similar sales are often seen at comparable pharmaceutical companies such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals, where executives may periodically exercise stock options or sell shares for personal financial management.
- The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations, mirroring practices at companies like Pfizer and Johnson & Johnson.
Stakeholder Impact
- The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 11/14/2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| 04/11/2025 | Date of the transaction (sale of shares) |
| 04/15/2025 | Date of signature on the Form 4 filing |
Keywords
Mineralys Therapeutics, Adam Levy, Form 4, Share Sale, 10b5-1 Trading Plan, CFO, MLYS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.